Can semaglutide lower the likelihood of dementia?

The glucagon-like peptide 1 agonist semaglutide may help reduce the risk of dementia.

In a retrospective study, published in eClinicalMedicine, investigators used electronic health records from the TriNetX U.S. Collaborative Network to examine the risk of adverse neurologic and psychiatric outcomes in patients with Type 2 diabetes mellitus who received semaglutide, or the antidiabetic medications sitagliptin, empagliflozin and glipizide between Dec. 1, 2017, and May 31, 2021.

The investigators found that semaglutide was not associated with adverse neurologic or psychiatric outcomes but was linked to a lower risk of cognitive deficit, dementia and nicotine misuse compared with the other medications included in the study.

The investigators concluded that despite the positive findings, the results of the study require validation in future clinical trials.

Read more: eClinicalMedicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.